Biography

Jay D. Horton obtained his B.S. and M.D. degrees from the University of Iowa in 1984 and 1988, respectively. He completed his internal medicine residency (1988-1991) and gastroenterology fellowship (1991-1994) at UT Southwestern Medical Center. During his gastroenterology fellowship he studied metabolic regulators of bile acid and cholesterol homeostasis in animals. Following the gastroenterology fellowship, he completed a Howard Hughes post doctoral fellowship in the Department of Molecular Genetics at UT Southwestern Medical Center. The studies in this fellowship focused on the transcriptional regulation of cholesterol and fatty acid synthesis.

In clinical digestive diseases, Dr. Horton has an interest in conditions that lead to steatosis and obesity. Currently the laboratory is investigating molecular mediators of steatosis using various mouse models. Investigations from the laboratory have revealed how the primary transcriptional regulators of cholesterol metabolism (sterol regulatory element-binding proteins) are also key regulators of fatty acid synthesis in liver.

A major focus of the laboratory is to determine how these transcriptional regulators contribute to the development of steatosis in various disease processes such as diabetes, obesity, and beta-oxidation defects.

A second area of investigation centers on determining the function of PCSK9, a protein that is involved in determining plasma LDL cholesterol levels through its ability to post-transcriptionally regulate the expression of the LDL receptor in liver.

Education

Medical School
University of Iowa Hospitals and Clinics (1988)
Internship/Residency
Parkland Health and Hospital System (1991), Internal Medicine
Fellowship
UT Southwestern Medical Center (1994), Gastroenterology
Fellowship
UT Southwestern Medical Center (1997), Molecular Genetics

Specialty Areas

Clinical Interest

  • Internal Medicine

Research Interest

  • Hepatic steatosis
  • Lipid metabolism

Publications

Featured Publications LegendFeatured Publications

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A Lancet 2014 Jan 383 9911 60-8

Honors & Awards

  • Association of American Physicians
    (2008)
  • American Society for Clinical Investigation
    (2003)
  • Established Investigator
    American Heart Foundation (2000)
  • PEW Scholar
    PEW Foundation (2000)
  • Research Scholar Award
    American Digestive Health Foundation (1999)